Cipla gets USFDA nod for contraceptive injection
The injection is indicated only for the prevention of pregnancy.
By PTI |
New Delhi: Drug firm Cipla on Monday said it has received final nod from the US health regulator for its Medroxyprogesterone injectable for prevention of pregnancy.
The company has received final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Medroxyprogesterone injectable 150mg/mL.
The product is a generic version of Pfizer's Depo-Provera, it added.
Depo-Provera and its generic equivalents had US sales of around USD 159 million for the 12-month period ending November 2018, Cipla further said.
The injection is indicated only for the prevention of pregnancy.
Shares of Cipla Monday were trading at Rs 493.70 per scrip on the BSE, down 2.60 per cent from the previous close.
The company has received final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Medroxyprogesterone injectable 150mg/mL.
The product is a generic version of Pfizer's Depo-Provera, it added.
Depo-Provera and its generic equivalents had US sales of around USD 159 million for the 12-month period ending November 2018, Cipla further said.
The injection is indicated only for the prevention of pregnancy.
Shares of Cipla Monday were trading at Rs 493.70 per scrip on the BSE, down 2.60 per cent from the previous close.
ADVERTISEMENT
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
Related Articles
Alembic Pharma gets tentative nod from USFDA for generic cancer drugADVERTISEMENT
